Navigation Links
Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger
Date:6/13/2010

CHAPEL HILL, N.C., June 11 /PRNewswire/ -- The bio-pharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth, and Merck + Schering-Plough - are now in the critical post-integration period and the acquiring companies are finding out how well they planned and executed their integration plans.

It is too early for final verdicts, but clearly one M&A issue that continues to create problems for the industry is integration of corporate cultures. Experienced integration leaders develop specific processes and approaches to assess the culture of M&A targets and then continuously assess and monitor to ensure the cultures integrate along with operations.

A recent Best Practices, LLC study found that while corporate culture was rated as a highly important risk-assessment factor for a successful integration, cultural assessments were rated as a less effective pre-integration planning activity due to accuracy.

Understanding and managing cultural issues is just one of the topics addressed in the 107-page report entitled M&A Integration Excellence: What Bio-Pharma Companies Need to Know (http://www3.best-in-class.com/rr1003.htm).  

This report utilizes a litany of benchmark metrics and executive insights gathered from industry surveys and interviews with bio-pharma executives to assess current trends and future directions of activity. The study featured participation from 26 organizations, including such influential companies as Pfizer, Eli Lilly, Johnson & Johnson and Abbott.

Key topic areas in the research include:

  • Structure for Integration
  • Pre-Integration Planning Activities
  • Integration Risk Management
  • Integration Functional Excellence
  • Communications Excellence
  • Understanding & Managing Cultural Issues
  • Post-Deal Closure Integration Activities
  • Trends in M&A Integration

The pace of merger and acquisition activity in the bio-pharma sector remains steady as organizations continue to seek external opportunities to grow their pipelines. This data-rich report addresses key M&A issues and identifies proven practices and key success factors in the M&A integration process among pharmaceutical and biotechnology companies.

Key questions this study addresses include:

  • What are the keys to successful M&A integration planning?
  • What structure, processes and best practices lead to M&A integration excellence?
  • What are the key risk factors to assess and manage in the M&A integration process?
  • How is success of the M&A integration function best measured and represented?
  • What are the critical success factors and pitfalls in the integration process?

To download a complimentary study excerpt, or to view a sample of key topics and study findings, go to: http://www3.best-in-class.com/rr1003.htm.

To learn more about Best Practices' other timely research visit: http://www3.best-in-class.com or contact James Drake at 919-767-9242 or jdrake@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
2. Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):